Baxter has hopes for hemophilia treatment
By Becky Bowman Medill News Service
Posted February 01, 2004
Baxter International Inc. executives predicted sales of the company's new hemophilia treatment Advate will continue to climb in 2004, in part because they expect approval in Europe soon.
The Food and Drug Administration approved Advate, a human and animal protein- and albumin-free clotting treatment, in July 2003. A fourth-quarter sales figure was not available for the treatment, but it generated $11 million in third-quarter sales.
Source: http://www.dailyherald.com/business/business%5fstory.asp?intid=38018131
[Editor: The preceding article was not written by A4M/WHN]
